General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2022-05-05 | 2022-03 | 0 | N/A | N/A | N/A |
2022-02-17 | 2021-12 | 0 | N/A | N/A | N/A |
2021-11-08 | 2021-09 | 0 | N/A | N/A | N/A |
2021-08-05 | 2021-06 | -0.09 | N/A | N/A | N/A |
2021-05-06 | 2021-03 | 0 | N/A | N/A | N/A |
2021-02-10 | 2020-12 | -0.04 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2020-08-27 | UBS | Upgrade | Buy | |
2020-08-10 | UBS | Upgrade | Buy | |
2019-11-06 | Janney Capital | Downgrade | Buy | Neutral |
2019-10-18 | UBS | Upgrade | Neutral | Buy |
2019-03-15 | UBS | Upgrade | Neutral | |
2019-03-14 | BTIG Research | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-03-31 | BARTHELEMY NICOLAS M | Director | 0.00 | Conversion of Exercise of derivative security |
2021-05-24 | BURBACH GERHARD F | Director | 65.91K | Stock Award(Grant) |
2021-05-24 | CLAGUE LAURA M | Director | 47.50K | Stock Award(Grant) |
2021-05-24 | COLSTON BILL W. JR., PH.D. | Director | 28.37K | Stock Award(Grant) |
2022-02-21 | JOG VIKRAM | Chief Financial Officer | 186.27K | Conversion of Exercise of derivative security |
2022-02-21 | KHADDER NICHOLAS S | General Counsel | 82.39K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2021-12-30 | Indaba Capital Management, L.P. | 7.45M | 29.19M | 9.74% |
2021-12-30 | Blackrock Inc. | 6.25M | 24.50M | 8.17% |
2021-12-30 | Primecap Management Company | 5.09M | 19.97M | 6.66% |
2021-12-30 | Neuberger Berman Group, LLC | 4.20M | 16.45M | 5.49% |
2021-12-30 | Vanguard Group, Inc. (The) | 3.87M | 15.16M | 5.06% |
2021-12-30 | Orbimed Advisors LLC. | 3.82M | 14.97M | 4.99% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-01-30 | Primecap Odyssey Aggressive Growth Fund | 4.08M | 13.33M | 5.33% |
2021-12-30 | Needham Small Cap Growth Fund | 3.43M | 13.43M | 4.48% |
2021-12-30 | Vanguard Total Stock Market Index Fund | 2.41M | 9.44M | 3.15% |
2021-12-30 | iShares Russell 2000 ETF | 1.77M | 6.94M | 2.31% |
2021-12-30 | Neuberger & Berman Intrinsic Value Fd | 1.18M | 4.64M | 1.55% |
2022-01-30 | TIAA-CREF Funds-Quant Small Cap Equity Fund | 1.04M | 3.41M | 1.36% |
$FLDM managed by people from Wash U! And looks like a contract now on the way being significant use and ease of use product.
$FLDM Be Greedy When Others Are Fearful
This is a classic example of what could have been. Everything looked so good and everyone was so excited, even the short seller Citron. Yet, sometimes destiny does not side with you and leaves you in a rotten mess. Know when to fold them. Looking for the next one but be careful with the current correction.
I say this as a fellow investor who got out earlier, you need to seriously consider getting out. The market is correcting and ALL COVID testing companies have been dropping consistently for the past 2 weeks. Testing companies are not profitable and the market knows that the testing will come to an end very soon. Just keeping it real.
I can’t believe that I am saying this, but I wish we were more like SRNE and only dropping 2 percent a day rather that this joke of a stock dropping 5 to 10 percent a day since the EUA. Who knew, FLDM is more the P and D stock than SRNE!!!!
We are truly living in an inverse universe. Real companies are fake, fake companies real. Socialist countries embracing democracy and America turning to soclialists like Sanders, Biden, AOC and embracing communism.
If FLGT spikes on agreement with NYC, one can only imagine what any contracts will do to FLDM. Question is how much pain can you tolerate until then. Also looming in the background is the possible vaccine approval prior to completion of P3 which is a strong possibility of happening. If it was easy, everyone would be millionaires.